In this guest blog, Lee Smith and Spiros Servos argue that early-stage biotech leaders who secure investment in 2026 are those who integrate commercial thinking early, aligning science, clinical strategy and market realities into a credible narrative for investors.
Coulter Partners successfully led a search for Babraham Research Campus Ltd (BRCL) and is pleased to announce the placement of Dr. Rich Ferrie as Chief Executive Officer (CEO).
Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, has appointed Edwin Moses as Chair of the Board of Directors, with immediate effect.
Some of the UK’s most ambitious early-stage life science companies are choosing Victoria House as their London base, adding fresh momentum to one of the capital’s most exciting life science communities.
In this guest blog, Dan Stanton, Trade Media Expert at Sartorius Bioprocess Solutions, discusses how tight funding, manual tech transfer and product specific analytics are keeping cell and gene therapies (CGTs) from realising their potential.
Back from our Easter break, we’re hitting the ground running with an update on the publication of agreed text underpinning the UK-US pharmaceuticals agreement.
In this guest blog, Paul Jeffrey, Director of the GFIL/Cranfield Technology Accelerator at Cranfield Water Science Institute, explains how engineering biology solutions for environmental applications face unclear and complex regulatory pathways.
Fermtech has raised £2.5m to scale Koji Cocoa™, a fermentation-based cocoa ingredient made from cocoa shells that delivers 25–33% cost savings and up to 98% lower carbon emissions.
British Growth Partnership Fund I achieves a first close of £200 million, with commitments from Aegon UK, Cushon Master Trust, M&G, and the British Business Bank.
Charlotte Cane, MP for Ely and East Cambridgeshire, visited local life science companies on 31 March to see for herself how new medicines and medical technologies are being developed.
